GlobeNewswire
Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study
CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has completed enrollment and dosing of all participants in the Company’s Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (“TSC”), utilizing a transcutaneous oxygen monitoring (TCOM) device to evaluate the pharmacodynamic effects of TSC on peripheral tissue oxygenation. The TCOM trial is the first in a series of three short-term Oxygenation Trials that Diffusion plans to conduct in the United States in 2021. Together, these Oxygenation Trials will serve as a prospective exploration of the relationship between the level of TSC exposure (dose) and response (change in oxygenation) and the Company expects positive data from any of the three Oxygenation Trials, if obtained, will guide the next phases of TSC’s clinical development and commercialization plans. The Company intends to fund these three studies with cash-on-hand. The TCOM trial was a randomized, double blind, placebo controlled, pharmacokinetic and pharmacodynamic study of TSC that enrolled and dosed 30 healthy volunteers. Trial participants were randomized into one of six subgroups…
